Completed PHASE2 INTERVENTIONAL 3-arm NCT00761215

Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections

A Phase 2 Multi-Center, Randomized, Double-Blind, Non-Controlled Study Comparing the Safety, Tolerance, and Efficacy of TR-701 in Patients With Complicated Skin and Skin Structure Infections

Sponsor: Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Conditions Skin Diseases, Bacterial Skin Diseases, Infectious

Interventions TR-701 200 mg TR-701 300 mg TR-701 400 mg

Updated 10 times since 2017 Last updated: Nov 11, 2019 Started: Sep 17, 2008 Primary completion: Feb 24, 2009 Completion: Feb 24, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Skin Diseases, Bacterial and Skin Diseases, Infectious, this trial is completed. The trial is conducted by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) and has accumulated 10 data snapshots since 2008. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2024 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Jan 2024 [monthly]

Completed PHASE2
Dec 2019 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 5 earlier versions

Sep 2018 — Dec 2019 [monthly]

Completed PHASE2
Jun 2018 — Sep 2018 [monthly]

Completed PHASE2
Oct 2017 — Jun 2018 [monthly]

Completed PHASE2
Feb 2017 — Oct 2017 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Sep 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Data source: Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Chula Vista, United States , Columbus, United States , Detroit, United States , Dothan, United States , Long Beach, United States , Ludowici, United States , Oceanside, United States , Pasadena, United States , San Francisco, United States , San Jose, United States and 2 more locations